Livanova PLC 10-Q quarterly reports

LivaNova PLC's Q2 2026 filing shows robust revenue increases in both Cardiopulmonary and Neuromodulation segments, alongside improved net income, though litigation provisions and R&D expenses present ongoing considerations.

LivaNova PLC reports a net income of $22.3 million for Q1 2026, a significant turnaround from a $327.3 million loss in Q1 2025, driven by strong revenue growth in both Cardiopulmonary and Neuromodulation segments.

LivaNova reports strong revenue growth in Q3 2025, driven by Cardiopulmonary and Neuromodulation segments, but faces a significant net loss for the nine-month period due to a large environmental liability.

LivaNova reported strong revenue and operating income growth in Q2 2025, overshadowed by a significant one-time environmental liability charge from the SNIA litigation.

LivaNova PLC reports its Q1 2025 results, showing revenue growth but a significant net loss due to a substantial charge related to the SNIA environmental liability.

LivaNova PLC's Q3 2024 results show a significant increase in revenue and a return to profitability, driven by strong performance in its Cardiopulmonary and Neuromodulation segments.

LivaNova PLC's second quarter results show a net income of $16.3 million, alongside a restructuring plan impacting its segments.

LivaNova's Q1 2024 results show a net loss, impacted by restructuring and debt extinguishment costs, despite revenue growth in both Cardiopulmonary and Neuromodulation segments.